Introduction ROS1 rearrangement–positive NSCLC can be treated effectively with an
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …

Background ROS1-rearranged lung cancers benefit from first-line crizotinib therapy;
however, clinical and molecular factors that could affect crizotinib efficacy in ROS1 …

Abstract Background Approximately 1–2% of patients with non‒small-cell lung cancer
(NSCLC) harbor ROS1 rearrangements. Crizotinib, an oral small-molecule tyrosine kinase …

Abstract Objectives Food and Drug Administration (FDA) approved crizotinib for advanced
ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single …

ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer
(NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) …

ROS1 gene rearrangements have been reported in diverse cancer types including non‐
small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung …

Background ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung
cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed …

Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

Introduction ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic
efficacy of crizotinib in this subset has been shown in early phase trials in the United States …

Background In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor
activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC) …